Compare VATE & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VATE | BDSX |
|---|---|---|
| Founded | 1994 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Precision Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.3M | 62.5M |
| IPO Year | 1996 | 2020 |
| Metric | VATE | BDSX |
|---|---|---|
| Price | $4.95 | $6.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | 31.8K | ★ 66.9K |
| Earning Date | 11-12-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,099,900,000.00 | $80,173,000.00 |
| Revenue This Year | N/A | $20.75 |
| Revenue Next Year | N/A | $25.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 22.29 |
| 52 Week Low | $4.05 | $3.44 |
| 52 Week High | $13.79 | $31.20 |
| Indicator | VATE | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 49.52 | 41.71 |
| Support Level | $4.75 | $6.56 |
| Resistance Level | $5.35 | $7.03 |
| Average True Range (ATR) | 0.37 | 0.59 |
| MACD | 0.05 | -0.15 |
| Stochastic Oscillator | 57.14 | 22.12 |
Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments which are; The infrastructure segment is comprised of DBM Global Inc, a fully integrated industrial construction, structural steel, and facility maintenance provider that provides fabrication and erection of structural steel and heavy steel plate services, The Life Sciences segment is comprised of Pansend Life Sciences which seeks to develop products to treat early osteoarthritis of the knee and aesthetic and medical technologies for the skin, and Spectrum segment is comprised of HC2 Broadcasting Holdings Inc which operates over-the-air broadcasting station across the United States.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.